RAG-17 is an experimental RNA-targeting therapy designed to lower toxic SOD1 protein in people with SOD1-ALS. A six-person trial found RAG-17 was well tolerated, with no serious side effects. RAG-17 ...

Although I continue to rely on a rollator to help me walk inside the house and a mobility scooter when I’m out and about, getting the power wheelchair was a strategic, planning-ahead decision. I live ...

Study examines Qalsody safety after approval “This study is the first to systematically conduct a post-marketing [safety] ...

A PBS documentary, "Loving John," explores a gay American Samoan man's final years with ALS. It highlights the disease's ...

Over the last five years, Canadian ALS clinics have shifted from offering genetic testing mainly to people with a family ...